|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Crestor film-coated tab[冠脂妥 膜衣錠] information |
|
|
|
製造商 |
AstraZeneca |
|
代理/經銷商 |
AstraZeneca |
|
成份 |
Rosuvastatin Ca |
|
適應症 |
As adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL-C, & triglycerides & to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. As adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. As adjunctive therapy to other lipid-lowering treatments (eg, LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, & ApoB in adult patients with homozygous familial hypercholesterolemia. |
|
用量 |
Hyperlipidemia, mixed dyslipidemia & hypertriglyceridemia 5-20 mg once daily. Usual starting dose: 10 mg once daily. Initiation of therapy with 5 mg once daily should be considered for patients requiring less aggressive LDL-C reductions, who have predisposing factors for myopathy, patients taking cyclosporine, Asian patients & patients with severe renal insufficiency. For patients with marked hypercholesterolemia (LDL-C > 190 mg/dL) & aggressive lipid targets, a 20-mg starting dose may be considered. When initiating statin therapy or switching from another statin therapy, the appropriate starting dose should first be utilized, & only then titrated according to the patient's individualized goal of therapy. Homozygous familial hypercholesterolemia Starting dose: 20 mg once daily. Response to therapy should be estimated from pre-apheresis LDL-C levels. |
|
過量 |
View Crestor[冠脂妥] overdosage for action to be taken in the event of an overdose. |
|
用法 |
May be taken with or without food |
|
美國食品藥物管理局之懷孕等級 |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
禁忌 |
Active liver disease including unexplained, persistent elevations of serum transaminases & any serum transaminase elevation exceeding 3 times the upper limit of normal; pregnancy & lactation. |
|
注意事項 |
Patients with predisposing factors for myopathy (eg. age ≥ 65 years, inadequately treated hypothyroidism, renal impairment). Therapy should be discontinued if markedly elevated creatinine kinase levels occur or myopathy is diagnosed or suspected. Therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg. sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders, or uncontrolled seizures). All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Liver enzyme tests should be performed before & at 12 weeks following both the initiation of therapy & any elevation of dose, & periodically (eg. semiannually) thereafter. Patients who consume substantial quantities of alcohol &/or have a history of chronic liver disease. Concomitant administration with anticoagulants. INR should be determined before starting therapy & frequently enough during early therapy to ensure that no significant alteration of INR occurs. Patients with unexplained persistent proteinuria &/or hematuria during routine urinalysis testing. Concomitant administration with drugs that may decrease the levels or activity of endogenous steroid hormones such as ketoconazole, spironolactone & cimetidine. |
|
不良反應 |
Headache, myalgia, abdominal pain, asthenia, nausea.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Cyclosporin, gemfibrozil, lopinavir & ritonavir combination, coumarin anticoagulants, niacin, other fibrates, ketoconazole, spironolactone, cimetidine.
View more drug interactions with Crestor[冠脂妥] |
|
儲存 |
View Crestor[冠脂妥] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Crestor[冠脂妥] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Crestor[冠脂妥] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Crestor 膜衣錠 |
|
Crestor 5 mg |
|
Crestor 10 mg |
 |
|
Crestor 20 mg |
|
|
|
Manufacturer: |
AstraZeneca |
|
Distributor: |
AstraZeneca
|
|
|
|
